SUPPLEMENTAL MATERIAL

Supplemental Table 1. Patient characteristics in bleeding versus no bleeding by BARC type 3 or 5.

Overall 1-year bleeding Non-bleeding

Variables p-valuea
(n=904) (n=154) (n=750)
Age, year 65.5 ± 10.5 72.0 ± 8.9 64.1 ± 10.3 <0.001
Female, n (%) 271 (30.0) 74 (48.1) 197 (26.3) <0.001
2
BMI, kg/m 24.4 ± 3.2 23.5 ± 3.3 24.6 ± 3.1 <0.001
Diagnosis, n (%) <0.001
Angina 593 (65.6) 70 (45.5) 523 (69.7)
NSTEMI 261 (28.9) 68 (44.2) 193 (25.7)
STEMI 50 (5.5) 16 (10.4) 34 (4.5)
Prior antiplatelet therapy, n(%) 472 (52.2) 78 (50.6) 394 (52.5) 0.368
Risk factor, n (%)
Diabetes mellitus 384 (42.5) 77 (50.0) 307 (40.9) 0.024
Hypertension 595 (65.8) 129 (79.9) 472 (62.9) <0.001
Dyslipidemia 516 (57.1) 83 (53.9) 433 (57.7) 0.215
Current smoking 240 (26.5) 30 (19.5) 210 (28.0) 0.017
Past history, n (%)
Prior MI 219 (24.2) 36 (23.4) 183 (24.4) 0.438
Prior PCI 369 (40.8) 58 (37.7) 311 (41.5) 0.217
Prior Stroke 93 (10.3) 27 (17.5) 66 (8.8) 0.002
Heart rate, bpm 75.1 ± 15.4 83.5 ± 19.5 73.4 ± 13.8 <0.001
Systolic BP, mmHg 130.1 ± 22.7 131.9 ± 27.1 129.7 ± 21.7 0.268
LVEF, % 58.9 ± 11.0 55.5 ± 12.5 59.7 ± 10.5 <0.001
Total cholesterol, mg/dl 163.8 ± 40.7 166.5 ± 48.7 163.3 ± 39.1 0.404
HbA1c, % 6.6 ± 1.3 6.8 ± 1.3 6.6 ± 1.3 0.305
6
White blood cell count (10 /mL) 7.9 ± 3.0 8.8 ± 3.9 7.8 ± 2.8 <0.001
3ul
Platelet count, 10 211.2 ± 62.1 214.3 ± 78.4 210.6 ± 58.2 0.498
Haemoglobin, g/dl 12.8 ± 2.0 11.2 ± 2.1 13.1 ± 1.7 <0.001
-1 -2
eGFR, mL min , 1.73 m 76.1 ± 26.1 62.7 ± 30.4 79.1 ± 24.1 <0.001
P2Y12 Inhibitors, n (%) 0.186
Clopidogrel 858 (94.9) 144 (93.5) 714 (95.2)
Prasugrel 39 (4.3) 7 (4.5) 32 (4.3)
Ticagrelor 7 (0.8) 3 (1.9) 4 (0.5)
Bleeding risk scores
CRUSADE 31.0 ± 14.2 43.7 ± 14.7 28.4 ± 12.6 <0.001
ACUITY 12.3 ± 6.8 18.7 ± 6.3 11.0 ± 6.1 <0.001
PRECISE-DAPT 22.0 ± 12.9 34.4 ± 12.5 19.5 ± 11.4 <0.001

Values are n (%) or mean ± SD. a Between bleeding and non-bleeding group. BMI, body mass index;
NSTEMI, non ST elevation myocardial infarction; STEMI, ST elevation myocardial infarction; MI,
myocardial infarction; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary
intervention; Hb, haemoglobin; eGFR, estimated glomerular filtration rate
Supplemental Table 2. Patient characteristics in bleeding versus no bleeding by TIMI minor or major.

Overall 1-year bleeding Non-bleeding

Variables p-valuea
(n=904) (n=119) (n=785)
Age, year 65.5 ± 10.5 71.8 ± 8.7 64.5 ± 10.4 <0.001
Female, n (%) 271 (30.0) 55 (46.2) 216 (27.5) <0.001
2
BMI, kg/m 24.4 ± 3.2 23.6 ± 3.2 24.5 ± 3.1 0.005
Diagnosis, n (%) 0.002
Angina 593 (65.6) 60 (50.4) 533 (67.9)
NSTEMI 261 (28.9) 47 (39.5) 214 (27.3)
STEMI 50 (5.5) 12 (10.1) 38 (4.8)
Prior antiplatelet therapy, n(%) 472 (52.2) 57 (47.9) 415 (52.9) 0.181
Risk factor, n (%)
Diabetes mellitus 384 (42.5) 58 (48.7) 326 (41.5) 0.084
Hypertension 595 (65.8) 94 (79.0) 501 (63.8) 0.001
Dyslipidemia 516 (57.1) 59 (49.6) 457 (58.2) 0.047
Current smoking 240 (26.5) 26 (21.8) 214 (27.3) 0.127
Past history, n (%)
Prior MI 219 (24.2) 26 (21.8) 193 (24.6) 0.300
Prior PCI 369 (40.8) 43 (36.1) 326 (41.5) 0.155
Prior Stroke 93 (10.3) 17 (14.3) 76 (9.7) 0.088
Heart rate, bpm 75.1 ± 15.4 83.9 ± 20.8 73.8 ± 14.0 <0.001
Systolic BP, mmHg 130.1 ± 22.7 130.2 ± 27.1 130.0 ± 22.0 0.952
LVEF, % 58.9 ± 11.0 55.4 ± 12.6 59.5 ± 10.6 <0.001
Total cholesterol, mg/dl 163.8 ± 40.7 165.9 ± 46.1 163.5 ± 39.9 0.565
HbA1c, % 6.6 ± 1.3 6.8 ± 1.3 6.6 ± 1.3 0.372
6
White blood cell count (10 /mL) 7.9 ± 3.0 8.7 ± 3.9 7.8 ± 2.8 0.003
3ul
Platelet count, 10 211.2 ± 62.1 214.4 ± 72.9 210.7 ± 60.3 0.541
Haemoglobin, g/dl 12.8 ± 2.0 11.6 ± 2.0 13.0 ± 1.9 <0.001
-1 -2
eGFR, mL min , 1.73 m 76.1 ± 26.1 66.4 ± 29.3 77.5 ± 25.3 <0.001
P2Y12 Inhibitors, n (%) 0.186
Clopidogrel 858 (94.9) 111 (93.3) 747 (95.2)
Prasugrel 39 (4.3) 7 (5.9) 32 (4.1)
Ticagrelor 7 (0.8) 1 (0.8) 6 (0.8)
Bleeding risk scores
CRUSADE 31.0 ± 14.2 41.0 ± 14.0 29.5 ± 13.6 <0.001
ACUITY 12.3 ± 6.8 17.6 ± 6.3 11.5 ± 6.4 <0.001
PRECISE-DAPT 22.0 ± 12.9 31.7 ± 11.8 20.5 ± 12.4 <0.001

Values are n (%) or mean ± SD. a Between bleeding and non-bleeding group. BMI, body mass index;
NSTEMI, non ST elevation myocardial infarction; STEMI, ST elevation myocardial infarction; MI,
myocardial infarction; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary
intervention; Hb, haemoglobin; eGFR, estimated glomerular filtration rate
Supplemental Table 3. Patient characteristics in bleeding versus no bleeding by GUSTO moderate or
severe.

Overall 1-year bleeding Non-bleeding

Variables p-valuea
(n=904) (n=80) (n=824)
Age, year 65.5 ± 10.5 71.4 ± 8.7 64.9 ± 10.5 <0.001
Female, n (%) 271 (30.0) 45 (56.3) 226 (27.4) <0.001
2
BMI, kg/m 24.4 ± 3.2 23.2 ± 3.5 24.5 ± 3.1 0.001
Diagnosis, n (%) 0.001
Angina 593 (65.6) 36 (45.0) 557 (67.6)
NSTEMI 261 (28.9) 35 (43.8) 226 (27.4)
STEMI 50 (5.5) 9 (11.3) 41 (5.0)
Prior antiplatelet therapy, n(%) 472 (52.2) 43 (53.8) 429 (52.1) 0.433
Risk factor, n (%)
Diabetes mellitus 384 (42.5) 39 (48.8) 345 (41.9) 0.142
Hypertension 595 (65.8) 67 (83.8) 528 (64.1) <0.001
Dyslipidemia 516 (57.1) 44 (55.0) 472 (57.3) 0.390
Current smoking 240 (26.5) 18 (22.5) 222 (26.9) 0.236
Past history, n (%)
Prior MI 219 (24.2) 20 (25.0) 199 (24.2) 0.479
Prior PCI 369 (40.8) 29 (36.3) 340 (41.3) 0.227
Prior Stroke 93 (10.3) 14 (17.5) 79 (9.6) 0.027
Heart rate, bpm 75.1 ± 15.4 84.1 ± 19.3 74.2 ± 14.7 <0.001
Systolic BP, mmHg 130.1 ± 22.7 134.7 ± 29.1 129.6 ± 22.0 0.053
LVEF, % 58.9 ± 11.0 54.6 ± 13.3 59.4 ± 10.7 <0.001
Total cholesterol, mg/dl 163.8 ± 40.7 170.3 ± 56.5 163.3 ± 39.1 0.167
HbA1c, % 6.6 ± 1.3 6.6 ± 1.1 6.6 ± 1.3 0.621
6
White blood cell count (10 /mL) 7.9 ± 3.0 8.4 ± 3.5 7.9 ± 3.0 0.119
3ul
Platelet count, 10 211.2 ± 62.1 215.4 ± 89.3 210.8 ± 58.8 0.525
Haemoglobin, g/dl 12.8 ± 2.0 11.3 ± 2.1 13.1 ± 1.7 <0.001
-1 -2
eGFR, mL min , 1.73 m 76.1 ± 26.1 54.1 ± 30.7 78.2 ± 24.6 <0.001
P2Y12 Inhibitors, n (%) 0.186
Clopidogrel 858 (94.9) 76 (95.0) 782 (94.9)
Prasugrel 39 (4.3) 2 (2.5) 37 (4.5)
Ticagrelor 7 (0.8) 2 (2.5) 5 (0.6)
Bleeding risk scores
CRUSADE 31.0 ± 14.2 47.1 ± 15.4 29.4 ± 13.1 <0.001
ACUITY 12.3 ± 6.8 19.1 ± 6.5 11.6 ± 6.4 <0.001
PRECISE-DAPT 22.0 ± 12.9 37.1 ± 12.6 20.6 ± 12.0 <0.001

Values are n (%) or mean ± SD. a Between bleeding and non-bleeding group. BMI, body mass index;
NSTEMI, non ST elevation myocardial infarction; STEMI, ST elevation myocardial infarction; MI,
myocardial infarction; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary
intervention; Hb, haemoglobin; eGFR, estimated glomerular filtration rate